Agenus Announces New Findings From Long-Term Survivor Analysis Of Phase 1b C-800-01 Trial Evaluating Botensilimab In Combination With Balstilimab In Heavily Pretreated Patients With MSS, mCRC Without Active Liver Metastases
Long-term survival of patients in the 123-patient Phase 1b CRC cohort was not limited to patients with favorable baseline characteristics, suggesting durable benefit may extend across a broader patient
Agenus found that cancer patients in their drug trial lived longer than expected. This hints the medicine might help many different types of patients, not just some.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.